Inovio Pharmaceuticals, Inc. (INO) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

9/25

Growth 2 Margin 1 Expansion 3 Platform 1 Financial 2

latest quarter score

Earnings Reports

9
INOVIO (INO) Q2 2026: $18.6M Operating Expenses Reflect Focused Investment Ahead of INO-3107 Launch
August 13, 2026
10
Inovio (INO) Q1 2026: Cash Runway Extended to Q1 2027 as INO3107 Nears FDA Milestone
May 14, 2026
9
Inovio (INO) Q4 2025: Operating Expenses Drop 23% as INO3107 FDA Review Drives Resource Focus
March 13, 2026
7
Inovio (INO) Q3 2025: Operating Expenses Cut 22% as 3107 BLA Submission Drives Strategic Focus
November 11, 2025
7
Inovio (INO) Q2 2025: Operating Expenses Drop 31% as 3107 Nears BLA Submission
August 13, 2025
10
Inovio Pharmaceuticals (INO) Q1 2025: Advancing INO-3107 BLA Submission with 72-Week Durable DMAb Proof of Concept
May 13, 2025
12
Inovio Pharmaceuticals (INO) Q4 2024: Advancing BLA Submission with 50% Complete Response in Year Two Strengthens Commercial Outlook
March 18, 2025

Browse all companies